Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma

Kim, Ji Sung; Chung, In-Sung; Lim, Sung Cil; Park, Yunsoo; Park, Ju Hee; Kim, Ju Young; Kim, Yong Guk; Hong, Jin Tae; Kim, Youngsoo; Han, Sang‐Bae

doi:10.1007/s12272-014-0381-x

Cited by 12 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, novel therapeutic approaches to prolong survival are required, particularly for patients at the advanced stage. Immunotherapy is a novel treatment for various types of tumor, including renal cell carcinoma (RCC), and has achieved encouraging results (7). Numerous studies have demonstrated the anti-tumor properties of cytokine-induced killer (CIK) cells, such as enhanced cyto-CIK) cells, such as enhanced cytotoxic activity and resistance to Fas-mediated apoptosis (8).…”

Section: Introductionmentioning

confidence: 99%

Primitive neuroectodermal tumor of the kidney at the advanced stage: A case series of eight Chinese patients

et al. 2018

View full text Add to dashboard Cite

Abstract. Primitive neuroectodermal tumor (PNET) rarely occurs as a primary renal neoplasm. Renal (r)PNET is a rare but aggressive neoplasm with poor prognosis; the majority of patients are diagnosed as advanced stage at presentation and face a worse prognosis than patients with localized disease. The present study describes the diagnosis and management of eight cases of rPNET at an advanced stage, who were treated at two institutions [Lingnan Hospital (branch of The Third Affiliated Hospital) and the Cancer Center of Sun Yat-sen University, Guangzhou], from December 2004 to January 2013. The clinical and pathological results of all patients were retrospectively obtained. Kaplan-Meier analysis was performed to estimate patient survival. The study cohort comprised five males and three females. Radical nephrectomy was performed in seven cases, while the remaining case only received needle biopsy of the tumor. Five cases received adjuvant chemotherapy, while three received no further treatment after surgery. Of note, one case received cytokine-induced killer (CIK) cell immunotherapy combined with surgery and chemotherapy. The overall median survival was 20 months with a 3-year survival rate of 25%. The overall survival of the four patients who received adjuvant chemotherapy following surgery was 36 months, compared with 10 months in the three patients without further treatment. The patient who received CIK cell immunotherapy survived for 20 months. Based on the observations of the present and previous studies, surgical excision and chemotherapy are recommended for treating rPNET at advanced stage. Furthermore, the present study was the first to report on CIK cell immunotherapy for a patient with rPNET, indicating that it may be a promising optional treatment. However, further studies are required to validate the benefit of CIK cells and to establish an appropriate immunotherapy protocol.

show abstract

Section: Introductionmentioning

confidence: 99%

Primitive neuroectodermal tumor of the kidney at the advanced stage: A case series of eight Chinese patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In treated patients, the percentage of T cells (CD3 + , CD4 + and CD4 + CD8 + ), CD16 + monocytes, and CD3 + CD56 + natural killer T cells, the levels of interleukin-2, interleukin-12, tumor necrosis factor-α, interferon-γ, and nucleolar organizer region protein in the peripheral blood of cancer patients was significantly increased (Wang et al, 2014b). DC-CIK was feasible and effective in treating advanced renal cancer (Kim et al, 2014;Su et al, 2010). Wang et al showed an objective response rate (ORR) of 39% and a disease control rate (DCR) of as 75%.…”

Section: Clinical Trialsmentioning

confidence: 96%

Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside

Arafar¹

2014

Biomed Res Ther

View full text Add to dashboard Cite

Abstract-Cytokine-induced killer (CIK) cells are T effector cells generated by monocytes cultured and stimulated by cytokines. CIK cells were studied for more than 20 years ago. They can cause lysis of tumor cells that of both autologous and allogeneic origins, so that they were used in cancer treatment. This review aimed to summarize advancements of CIK cells and their current clinical applications in cancer treatment. In general, CIK cells were widely clinically used for recent 5 years. They gave promising results in hepatocellular carcinoma, lung cancer, breast cancer, renal cancer, and treatment. Looking into the future, CIK cell based immunotherapy will become an important tool in cancer treatment.

show abstract

“…CIK cells are created in vitro by harvesting peripheral mononuclear cells in the blood using an anti-CD3 antibody. The resulting phenotype by IL-1, IFNγ, and IL-2 shares features of effector T-cells and natural killer cells [130]. A phase II trial randomly assigned 148 patients with mRCC to CIK cell immunotherapy or IL-2 combined with IFNα [131].…”

Section: Perspectivementioning

confidence: 99%

Immunotherapy for Renal Cell Carcinoma

Qu¹,

Wu²,

He³

et al. 2020

Evolving Trends in Kidney Cancer

View full text Add to dashboard Cite

Despite the rapid development of therapeutic modalities for advanced or metastatic renal cell carcinoma (mRCC) over the past decade to include traditional immunotherapy, such as high-dose interleukin-2 and interferon-α, as well as a number of targeted antiangiogenic therapies, mRCC continues to be associated with poor prognosis. Currently, immunotherapy has seen tremendous development in the form of immune checkpoint inhibition and vaccines at a dizzying pace, which are being studied in mRCC and are showing promise as important steps in the management of this disease. With so many drugs available to clinicians and patients, properly integrating immunotherapy especially immune checkpoint blockade (ICB) into the treatment paradigm is challenging. Emerging research with additional ICB agents and novel combination strategies is likely to further impact clinical decision-making. The further development of biomarkers for predicting a response is required to achieve optimal efficacy with these therapeutic interventions. This chapter summarizes the current landscape of standard and emerging immune therapeutics and other modalities for mRCC.

show abstract

Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma

Cited by 12 publications

References 50 publications

Primitive neuroectodermal tumor of the kidney at the advanced stage: A case series of eight Chinese patients

Primitive neuroectodermal tumor of the kidney at the advanced stage: A case series of eight Chinese patients

Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside

Immunotherapy for Renal Cell Carcinoma

Contact Info

Product

Resources

About